Literature DB >> 3149241

Effect of hepatic and renal dysfunction on disposition of bupropion in rats.

J S Kaka1, K I Al-Khamis, M O Tanira.   

Abstract

Disposition of bupropion after oral administration was investigated in carbon tetrachloride (CCl4) and gentamicin treated rats. Bupropion exhibits extensive first-pass effect and is mainly cleared by hepatic route. In rats with hepatic damage, maximum plasma concentration (Cmax) was approximately 3 times higher and area under the plasma concentration-time curve up to 6 h (AUC 0-6) and AUC 0-infinity increased on an average 4 and 5 times respectively compared to the control. The half-life was doubled with hepatic dysfunction. These findings suggest that hepatic impairment in rats causes a decrease in first pass effect as well as an increase in the half-life of the drug. Rats with renal impairment, exhibited a significant increase in Cmax, AUC 0-6 and AUC 0-infinity of bupropion approximately 3-fold as compared to the control, no change in half life of the drug was observed. This indicates that rats with renal impairment show less efficient first-pass effect which may lead to increase in systemic bioavailability. The time to peak observed in all treated animals was not significantly different from the control. The percentage of bound bupropion did not differ either in CCl4 or gentamicin treated plasma as compared to the control.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3149241     DOI: 10.1007/BF03189933

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  17 in total

1.  Aminoglycoside nephrotoxicity.

Authors:  G J Kaloyanides; E Pastoriza-Munoz
Journal:  Kidney Int       Date:  1980-11       Impact factor: 10.612

Review 2.  Enzyme immunoassays in clinical chemistry: present status and trends.

Authors:  M Oellerich
Journal:  J Clin Chem Clin Biochem       Date:  1980-04

3.  The pharmacokinetics of metoclopramide in rats with experimental renal and hepatic dysfunction.

Authors:  Y K Tam; J E Axelson; B McErlane; R P Kapil; K W Riggs; R Ongley; J D Price
Journal:  J Pharmacol Exp Ther       Date:  1981-10       Impact factor: 4.030

4.  Pharmacological significance of the species differences in bupropion metabolism.

Authors:  R M Welch; A A Lai; D H Schroeder
Journal:  Xenobiotica       Date:  1987-03       Impact factor: 1.908

5.  Alcohol and bupropion pharmacokinetics in healthy male volunteers.

Authors:  J Posner; A Bye; S Jeal; A W Peck; P Whiteman
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Mechanisms of the defect in glomerular ultrafiltration associated with gentamicin administration.

Authors:  C Baylis; H R Rennke; B M Brenner
Journal:  Kidney Int       Date:  1977-11       Impact factor: 10.612

7.  Pathophysiology of altered glomerular function in aminoglycoside-treated rats.

Authors:  N Schor; I Ichikawa; H G Rennke; J L Troy; B M Brenner
Journal:  Kidney Int       Date:  1981-02       Impact factor: 10.612

8.  Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects.

Authors:  J W Findlay; J Van Wyck Fleet; P G Smith; R F Butz; M L Hinton; M R Blum; D H Schroeder
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

9.  Efficacy of bupropion in tricyclic-resistant or intolerant patients.

Authors:  W C Stern; N Harto-Truax; N Bauer
Journal:  J Clin Psychiatry       Date:  1983-05       Impact factor: 4.384

Review 10.  Clinical pharmacokinetics of bupropion: a review.

Authors:  A A Lai; D H Schroeder
Journal:  J Clin Psychiatry       Date:  1983-05       Impact factor: 4.384

View more
  1 in total

1.  Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites.

Authors:  Miia Turpeinen; Niina Koivuviita; Ari Tolonen; Petri Reponen; Stefan Lundgren; Jouko Miettunen; Kaj Metsärinne; Anders Rane; Olavi Pelkonen; Kari Laine
Journal:  Br J Clin Pharmacol       Date:  2007-03-01       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.